Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer

Prostate

Volumn 73, Issue 10, 2013, Pages 1057-1068

  Guimond, Marie Odile ^a   Battista, Marie Claude ^a   Nikjouitavabi, Fatemeh ^a   Carmel, Maude ^a   Barres, Véronique ^b   Doueik, Alexandre A ^c   Fazli, Ladan ^d   Gleave, Martin ^d   Sabbagh, Robert ^a   Gallo Payet, Nicole ^a  

^a UNIVERSITÉ DE SHERBROOKE   (Canada)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF SHERBROOKE   (Canada)

^d VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

angiotensin; AT2 receptor; cancer; human prostate; primary cell culture; proliferation

Indexed keywords

ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN 2 RECEPTOR INTERACTING PROTEIN; ANTINEOPLASTIC AGENT; C 21 M 024; HORMONE RECEPTOR AFFECTING AGENT; LOSARTAN; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER GROWTH; CELL STRUCTURE; CONTROLLED STUDY; EPITHELIUM CELL; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECEPTOR BINDING; TISSUE MICROARRAY; WESTERN BLOTTING;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; CELL PROLIFERATION; HUMANS; LOSARTAN; MALE; PROSTATE; PROSTATIC NEOPLASMS; RECEPTOR, ANGIOTENSIN, TYPE 2; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84878471383     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22653     Document Type: Article

References (49)

1. Crawford ED,. Understanding the epidemiology, natural history, and key pathways involved in prostate cancer. Urology 2009; 73 (5 Suppl): S4-S10.
2. Uzgare AR, Isaacs JT,. Prostate cancer: Potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005; 37 (4): 707-714.
3. Uemura H, Ishiguro H, Kubota Y,. Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008; 15 (1): 19-26.
4. Chow L, Rezmann L, Catt KJ, Louis WJ, Frauman AG, Nahmias C, Louis SN,. Role of the renin-angiotensin system in prostate cancer. Mol Cell Endocrinol 2009; 302 (2): 219-229.
5. Deshayes F, Nahmias C,. Angiotensin receptors: A new role in cancer ? Trends Endocrinol Metab 2005; 16 (7): 293-299.
6. Steckelings UM, Rompe F, Kaschina E, Namsolleck P, Grzesiak A, Funke-Kaiser H, Bader M, Unger T,. The past, present and future of angiotensin II type 2 receptor stimulation. J Renin Angiotensin Aldosterone Syst 2010; 11: 67-73.
7. Uemura H, Ishiguro H, Nakaigawa N, Nagashima Y, Miyoshi Y, Fujinami K, Sakaguchi A, Kubota Y,. Angiotensin II receptor blocker shows antiproliferative activity in prostate cancer cells: A possibility of tyrosine kinase inhibitor of growth factor. Mol Cancer Ther 2003; 2 (11): 1139-1147.
8. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y,. Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006; 66 (8): 822-830.
9. O'Mahony OA, Barker S, Puddefoot JR, Vinson GP,. Synthesis and secretion of angiotensin II by the prostate gland in vitro. Endocrinology 2005; 146 (1): 392-398.
10. Dinh DT, Frauman AG, Sourial M, Casley DJ, Johnston CI, Fabiani ME,. Identification, distribution, and expression of angiotensin II receptors in the normal human prostate and benign prostatic hyperplasia. Endocrinology 2001; 142 (3): 1349-1356.
11. Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J,. Inflammation and angiotensin II. Int J Biochem Cell Biol 2003; 35 (6): 881-900.
12. Fabiani ME, Hawkes DJ, Frauman AG, Tikellis C, Johnston CI, Wilkinson-Berka JL,. Regulation of angiotensin II receptors in the prostate of the transgenic (mRen-2)27 rat: Effect of angiotensin-converting enzyme inhibition. Int J Biochem Cell Biol 2003; 35 (6): 973-983.
13. Dominska K, Piastowska-Ciesielska AW, Lachowicz-Ochedalska A, Ochedalski T,. Similarities and differences between effects of angiotensin III and angiotensin II on human prostate cancer cell migration and proliferation. Peptides 2012; 37 (2): 200-206.
14. Dominska K, Piastowska-Ciesielska AW, Pluciennik E, Lachowicz-Ochedalska A, Ochedalski T,. A comparison of the effects of angiotensin IV on androgen-dependent and androgen-independent prostate cancer cell lines. J Renin Angiotensin Aldosterone Syst 2012; (in press).
15. Uemura H, Hasumi H, Kawahara T, Sugiura S, Miyoshi Y, Nakaigawa N, Teranishi J, Noguchi K, Ishiguro H, Kubota Y,. Pilot study of angiotensin II receptor blocker in advanced hormone-refractory prostate cancer. Int J Clin Oncol 2005; 10 (6): 405-410.
16. Ronquist G, Rodriguez LA, Ruigomez A, Johansson S, Wallander MA, Frithz G, Svardsudd K,. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58 (1): 50-56.
17. Verdonk K, Danser AH, van Esch JH,. Angiotensin II type 2 receptor agonists: Where should they be applied ? Expert Opin Investig Drugs 2012; 21 (4): 501-513.
18. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlof B, Unger T,. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2011; 11: 1-6.
19. Li H, Qi Y, Li C, Braseth LN, Gao Y, Shabashvili AE, Katovich MJ, Sumners C,. Angiotensin type 2 receptor-mediated apoptosis of human prostate cancer cells. Mol Cancer Ther 2009; 8 (12): 3255-3265.
20. Nouet S, Amzallag N, Li JM, Louis S, Seitz I, Cui TX, Alleaume AM, Di Benedetto M, Boden C, Masson M, Strosberg AD, Horiuchi M, Couraud PO, Nahmias C,. Trans-inactivation of receptor tyrosine kinases by novel angiotensin II AT2 receptor-interacting protein, ATIP. J Biol Chem 2004; 279 (28): 28989-28997.
21. Wruck CJ, Funke-Kaiser H, Pufe T, Kusserow H, Menk M, Schefe JH, Kruse ML, Stoll M, Unger T,. Regulation of transport of the angiotensin AT2 receptor by a novel membrane-associated Golgi protein. Arterioscler Thromb Vasc Biol 2005; 25 (1): 57-64.
22. Rodrigues-Ferreira S, Nahmias C,. An ATIPical family of angiotensin II AT2 receptor-interacting proteins. Trends Endocrinol Metab 2010; 21 (11): 684-690.
23. Di Benedetto M, Pineau P, Nouet S, Berhouet S, Seitz I, Louis S, Dejean A, Couraud PO, Strosberg AD, Stoppa-Lyonnet D, Nahmias C,. Mutation analysis of the 8p22 candidate tumor suppressor gene ATIP/MTUS1 in hepatocellular carcinoma. Mol Cell Endocrinol 2006; 252 (1-2): 207-215.
24. Rodrigues-Ferreira S, Di Tommaso A, Dimitrov A, Cazaubon S, Gruel N, Colasson H, Nicolas A, Chaverot N, Molinie V, Reyal F, Sigal-Zafrani B, Terris B, Delattre O, Radvanyi F, Perez F, Vincent-Salomon A, Nahmias C,. 8p22 MTUS1 gene product ATIP3 is a novel anti-mitotic protein underexpressed in invasive breast carcinoma of poor prognosis. PLoS ONE 2009; 4 (10): e7239.
25. Louis SN, Chow L, Rezmann L, Krezel MA, Catt KJ, Tikellis C, Frauman AG, Louis WJ,. Expression and function of ATIP/MTUS1 in human prostate cancer cell lines. Prostate 2010; 70 (14): 1563-1574.
26. Chow L, Rezmann L, Imamura K, Wang L, Catt K, Tikellis C, Louis WJ, Frauman AG, Louis SN,. Functional angiotensin II type 2 receptors inhibit growth factor signaling in LNCaP and PC3 prostate cancer cell lines. Prostate 2008; 68 (6): 651-660.
27. Martineau D, Lamouche S, Briand R, Yamaguchi N,. Functional involvement of angiotensin AT2 receptor in adrenal catecholamine secretion in vivo. Can J Physiol Pharmacol 1999; 77 (5): 367-374.
28. Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J,. Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: Molecular mechanisms. Circ Res 2000; 86 (12): 1266-1272.
29. Fabiani ME, Sourial M, Thomas WG, Johnston CI, Frauman AG,. Angiotensin II enhances noradrenaline release from sympathetic nerves of the rat prostate via a novel angiotensin receptor: Implications for the pathophysiology of benign prostatic hyperplasia. J Endocrinol 2001; 171 (1): 97-108.
30. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M,. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47 (24): 5995-6008.
31. Unger T, Dahlof B,. Compound 21, the first orally active, selective agonist of the angiotensin II type 2 (AT2) receptor: Implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 2010; 11: 75-77.
32. Diallo JS, Aldejmah A, Mouhim AF, Peant B, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F,. NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model. Clin Cancer Res 2007; 13 (23): 7044-7052.
33. Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Begin LR, Mes-Masson AM, Saad F,. Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: Potential implications for prostate cancer development and prognosis. BJU Int 2008; 101 (10): 1302-1309.
34. Ouellet V, Ling TH, Normandin K, Madore J, Lussier C, Barres V, Bachvarov D, Rancourt C, Tonin PN, Provencher DM, Mes-Masson AM,. Immunohistochemical profiling of benign, low malignant potential and low grade serous epithelial ovarian tumors. BMC Cancer 2008; 8: 346-354.
35. Gleason DF, Mellinger GT,. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974; 111 (1): 58-64.
36. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM,. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006; 119 (3): 599-607.
37. Guimond MO, Roberge C, Gallo-Payet N,. Fyn is involved in angiotensin II type 2 receptor-induced neurite outgrowth, but not in p42/p44mapk in NG108-1 cells. Mol Cell Neurosci 2010; 45 (3): 201-212.
38. Guimond MO, Wallinder C, Alterman M, Hallberg A, Gallo-Payet N,. Comparative functional properties of two structurally similar selective nonpeptide drug-like ligands for the angiotensin II type-2 (AT(2)) receptor. Effects on neurite outgrowth in NG108-15 cells. Eur J Pharmacol 2013; 699 (1): 160-171.
39. Battista MC, Guimond MO, Roberge C, Doueik AA, Fazli L, Gleave M, Sabbagh R, Gallo-Payet N,. Inhibition of DHCR24/seladin-1 impairs cellular homeostasis in prostate cancer. Prostate 2010; 70 (9): 921-933.
40. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY,. Transcriptomes of human prostate cells. BMC Genomics 2006; 7: 92-102.
41. Bosnyak S, Jones ES, Christopoulos A, Aguilar MI, Thomas WG, Widdop RE,. Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors. Clin Sci (Lond) 2011; 121 (7): 297-303.
42. Lin J, Freeman MR,. Transactivation of ErbB1 and ErbB2 receptors by angiotensin II in normal human prostate stromal cells. Prostate 2003; 54 (1): 1-7.
43. Vogel C, Marcotte EM,. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet 2012; 13 (4): 227-232.
44. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S, Kikkawa F,. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11 (7): 2686-2694.
45. Yamagishi T, Uemura H, Nakaigawa N, Noguchi K, Kubota Y,. Angiotensin II blocker decreases serum prostate specific antigen in hormone refractory prostate cancer. J Urol 2005; 173 (2): 441.
46. Uemura H, Ishiguro H, Nagashima Y, Sasaki T, Nakaigawa N, Hasumi H, Kato S, Kubota Y,. Antiproliferative activity of angiotensin II receptor blocker through cross-talk between stromal and epithelial prostate cancer cells. Mol Cancer Ther 2005; 4 (11): 1699-1709.
47. Rompe F, Artuc M, Hallberg A, Alterman M, Stroder K, Thone-Reineke C, Reichenbach A, Schacherl J, Dahlof B, Bader M, Alenina N, Schwaninger M, Zuberbier T, Funke-Kaiser H, Schmidt C, Schunck WH, Unger T, Steckelings UM,. Direct angiotensin II type 2 receptor stimulation acts anti-inflammatory through epoxyeicosatrienoic acid and inhibition of nuclear factor kappaB. Hypertension 2010; 55 (4): 924-931.
48. De Nunzio C, Kramer G, Marberger M, Montironi R, Nelson W, Schroder F, Sciarra A, Tubaro A,. The controversial relationship between benign prostatic hyperplasia and prostate cancer: The role of inflammation. Eur Urol 2011; 60 (1): 106-117.
49. Widdop RE, Matrougui K, Levy BI, Henrion D,. AT2 receptor-mediated relaxation is preserved after long-term AT1 receptor blockade. Hypertension 2002; 40 (4): 516-520.